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▼Genetic variation in the human population has been
studied to gain insight into the functional importance of
specific genes in disease and drug metabolism. For ex-
ample, polymorphic variants of genes that are important
in the regulation of blood pressure, blood clotting and
blood lipids are studied in relation to cardiovascular dis-
ease (Ref. 1). The relation of detoxification enzymes to can-
cer risk (Ref. 2, 3, 4, 5, 6, 7) and idiosyncratic drug effects
(Ref. 8, 9), the latter with the aim to obtain individual-
ized drug-therapy regimens, are the focus of world-wide ef-
forts. Individual genotyping can now be performed quickly
and easily by PCR-based methods utilizing minute quan-
tities of DNA. However, finding new unknown polymor-
phisms in a gene is a tedious task involving either a search
for restriction fragment length polymorphisms (RFLPs) on
Southern blots or PCR amplifications of suitably sized seg-
ments of the gene, followed by single-strand-conformation-
polymorphism (SSCP) analysis or direct DNA-sequence de-
termination. Because of the considerable interest in, and
plans of, cataloguing human DNA sequence variation (Ref.
10), improved methodology, including minisequencing
strategies, multiplex reverse dot blots, DNA chips and a
TaqMan approach is being developed. However, we show
here that a considerable amount of human DNA sequence
variants can be found in silico.
In our laboratory we are currently studying polymor-
phisms of human genes involved in blood pressure regu-
lation and atherosclerosis (Ref. 11), including a gene in-
volved in protection against oxidative stress (Ref. 2). Al-
together, five point mutations are now studied in the
angiotensinogen (Ref. 12), angiotensin II receptor type1
(Ref. 13) and glutathione transferase Pi (Ref. 2) genes.
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These polymorphisms were first identified by conventional
techniques. It occurred to us that the laborious task of
identifying new polymorphisms would be greatly simpli-
fied if they could be found in silico in the ‘expressed se-
quence tag’ EST database (Ref. 14). A BLAST (Ref. 15) search
(www.ncbi.nlm.nih.gov/BLAST/) of the NCBI EST database
sequences deposited (1182287) until 19th of September
1997 against the above full-length cDNAs revealed that all
five polymorphisms could be identified unambiguously in
high-quality regions of the corresponding EST sequences.
Table 1 summarizes the position of the polymorphic site in
the mRNA, the number of reported EST sequences for each
gene, the number of ESTs that cover the region of the poly-
morphism, the relative number of clones representing each
genotype and the reported allele frequencies. In general,
the gapped BLAST tool performs extremely well for identi-
fying polymorphisms because poor-quality sequence areas,
inevitably present in ESTs, do not appear in the alignments.
By this approach, we have identified and subsequently ver-
ified experimentally several new polymorphisms in genes
related to oxidative stress (not shown). Furthermore, splice
variants have also been identified in the EST database
(Ref. 16). However, the error rate in the EST database
does generate false positives and the optimal level of in-
dependent clones needed for high-confidence predictions
remains to be determined. Given the rapid rate at which
EST sequences are accumulating, the power of the present
approach will continue to increase. In order not to impair
chances of finding important polymorphisms, similar EST
sequences should not be filtered and deemed redundant un-
less they are equal in their high-quality sequence regions.
The number of individual human cDNA libraries listed in
dbEST is presently 50. The number of individuals repre-
sented is unclear, however, because pooled material was
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Table 1. Frequencies of five common polymorphisms in the EST databasea
(http://www.ncbi.nlm.nih.gov/)
Polymorphic site Total number of ESTs covering Reported allele
Gene (and mRNA size)b EST sequences the polymorphic site EST variants frequencies
AngiotensinogenT
M
C/T 659 (Ref. 17) 292 15 9/6 0.82/0.18 (Ref. 12)
T235M C/T 842 (2099)
(Ref. 17)
292 14 9/5 0.59/0.41 (Ref. 12)
Angiotensin II
receptor type1
3‘non-translated
A/C 1500 (2268)
(Ref. 18)
12 6 4/2 0.55/0.45 (Ref. 13)
Glutathione
transferase Pi
I104V
A/G 325 (719) (Ref. 2) 3697c 52 (OUT OF 100 EXAM-
INED)
39/13 0.60/0.40 (REF. 2)
A113V C/T 353 (719) (Ref. 2) 3697c 52 (OUT OF 100 EXAM-
INED)
49/3 0.75/0.25 (REF. 2)
aThe Genbank Identification Numbers of the individual clones is supplied as a separate list to the publishers.
bNucleotide number in, size of the published cDNA sequence (which are all close to full-length).
cThat match an IRX query for human glutathione S-transferase Pi at http://www.ncbi.nlm.nih.gov/dbEST/index.html. This search
engine will also find entries from other species, therefore the actual number is lower.
utilized in the preparation of some of the cDNA libraries.
Clearly, our results show that the number of individuals
represented suffices to identify common polymorphisms.
In conclusion, known genetic polymorphisms could be
unambiguously identified in the human EST database. It is
apparent that any search for new polymorphisms should
start in silico and that this approach will undoubtedly save
time and resources, allowing the biomedical community
to increase the pace of its research.
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